Anurag S. Rathore, PhD, wins a grant and the use of scientific instruments from Agilent to further his investigation.
Anurag S. Rathore, PhD, has become the first from India to receive the Agilent Technologies Thought Leader Award. Rathore was recognized for his contributions to biopharmaceutical research and his efforts to advance the molecular characterization of biosimilars.
The characterization of biosimilars is a process that helps determine the bioequivalence of these products to reference, or original, drugs. Characterization also establishes the nature and extent of differences between biosimilar candidates and their reference products and whether these are clinically meaningful.
As recipient of the award, Rathore receives Agilent equipment and a grant to support his research. He joins 47 others who have received the Agilent awards previously.
Agilent, a 1999 spinoff from Hewlett-Packard, is a Santa Clara, California–based analytical instrumentation developer and manufacturer.
Rathore is a professor and scientist at the Indian Institute of Technology (IIT) Delhi. He earned his PhD from Yale University and currently works in the Department of Chemical Engineering at ITT Delhi. He is a member of the Parenteral Drug Association and American Chemical Society and is the author of more than 400 publications and presentations. He is also editor-in-chief of Preparative Biochemistry and Biotechnology. Information about his publications can be accessed by clicking here.
Rathore recently spoke with The Center for Biosimilars® about a study he conducted on reasons that applications for biosimilar regulatory approval fail.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.